Bristol-Myers Squibb deploys Anthropic's Claude AI across 30,000 employees to speed drug discovery

Anthropic And OpenAI--Building Different Competitive Advantages - Bristol-Myers Squibb (NYSE:BMY)

What BMS Is Actually Deploying This is not a pilot program or a proof-of-concept experiment. According to a Business Wire press release posted on May 20, the partnership positions Claude Enterprise as BMS's shared intelligence platform across its entire global operations. That scope spans research, clinical development, manufacturing, commercial, and corporate functions. Additionally, BMS will also deploy Claude Code, Anthropic's AI-powered coding tool, across those same divisions. Furthermore, the shift from conversational AI toward agentic capability is the specific evolution BMS is betting on. That matters for investors. Agentic AI, where models autonomously connect systems and execute multi-step workflows, is where enterprise value becomes defensible and sticky. A firm that embeds Claude into its daily operational and scientific workflows is unlikely to switch vendors easily. Anthropic Is Building a Partnership Moat Separately, Anthropic formed a $200 million partnership with the Gates Foundation and joined forces with Blackstone, Goldman Sachs, and Hellman and Friedman to create a new AI services company targeting mid-sized enterprises. The pattern across these deals is consistent. Anthropic is embedding Claude into institutions where the cost of switching is high and the data environment is complex. OpenAI Is Playing a Different Game The Singapore move reflects a different competitive strategy. OpenAI is securing government-level partnerships and anchoring its international footprint in policy-friendly jurisdictions. Anthropic, by contrast, is securing depth inside regulated enterprise environments. Both strategies are rational. However, the BMS deal illustrates that regulated industries want AI embedded inside institutional workflows, not layered on top from a regional hub. Why This Matters for Investors For retail investors tracking this space, the BMS partnership signals that Claude enterprise AI is not chasing OpenAI's footprint. It is building a different kind of competitive advantage, one rooted in institutional depth rather than geographic reach. That distinction could prove consequential as agentic AI moves from concept to core infrastructure. Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy. Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery - Bristol-Myers Squibb (NYSE:BMY)

The collaboration aims to enhance the discovery and development of new medicines, leveraging Anthropic's advanced AI capabilities to connect over 30,000 employees with critical institutional knowledge. Bristol-Myers Squibb Partners With Anthropic To Deploy AI The partnership with Anthropic marks a significant step for Bristol-Myers Squibb in integrating AI into its workflows, focusing on areas expected to yield high impact. The initiative builds on over three years of AI investment at the company, aiming to streamline processes in research, clinical development, and manufacturing. The companies plan to use artificial intelligence, multimodal real-world data, and advanced data science tools to refine drug development strategies in oncology and neuroscience. The initiative will leverage Tempus' AI-enabled analytical platform, Lens, to analyze a large library of de-identified multimodal patient records. The companies said the collaboration is intended to strengthen Bristol Myers Squibb's development portfolio by testing trial assumptions, identifying appropriate patient populations, and improving control group validation. Top ETFs Holding Bristol-Myers Squibb Stock Significance: Because BMY carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock. BMY Price Action: Bristol-Myers Squibb shares were up 0.12% at $58.38 at the time of publication on Wednesday, according to Benzinga Pro data. Photo: Shutterstock Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

May 20 (Reuters) - Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines. o Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its use in research, drug development, manufacturing and other commercial and medical affairs. o Drugmakers have announced a slew of deals for tools to unleash the promise of artificial intelligence. o Many, including drugmaker Eli Lilly, which has partnered with leading chipmaker Nvidia, are betting AI can also improve the success rate of new drugs. o "Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it," said Greg Meyers, chief digital and technology officer at Bristol Myers. o Agentic AI, which requires little human intervention, could increase clinical development productivity by about 35% to 45% over the next five years, consultancy McKinsey said last year. (Reporting by Christy Santhosh in Bengaluru; Editing by Sahal Muhammed)